The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs

Christine Sekaggya-Wiltshire, Mohammed Lamorde, Agnes N. Kiragga, Kelly E. Dooley, Moses R. Kamya, Andrew Kambugu, Jan Fehr, Yukari C. Manabe, Barbara Castelnuovo

Research output: Research - peer-reviewReview article

Abstract

Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.

LanguageEnglish (US)
Pages77-82
Number of pages6
JournalTuberculosis
Volume108
DOIs
StatePublished - Jan 1 2018

Fingerprint

Tuberculosis
Pharmacokinetics
Pharmaceutical Preparations
Pulmonary Tuberculosis
Public Health
Therapeutics

Keywords

  • Anti-tuberculosis drugs
  • Concentrations
  • Treatment outcomes

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Sekaggya-Wiltshire, C., Lamorde, M., Kiragga, A. N., Dooley, K. E., Kamya, M. R., Kambugu, A., ... Castelnuovo, B. (2018). The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis, 108, 77-82. DOI: 10.1016/j.tube.2017.11.004

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. / Sekaggya-Wiltshire, Christine; Lamorde, Mohammed; Kiragga, Agnes N.; Dooley, Kelly E.; Kamya, Moses R.; Kambugu, Andrew; Fehr, Jan; Manabe, Yukari C.; Castelnuovo, Barbara.

In: Tuberculosis, Vol. 108, 01.01.2018, p. 77-82.

Research output: Research - peer-reviewReview article

Sekaggya-Wiltshire, C, Lamorde, M, Kiragga, AN, Dooley, KE, Kamya, MR, Kambugu, A, Fehr, J, Manabe, YC & Castelnuovo, B 2018, 'The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs' Tuberculosis, vol 108, pp. 77-82. DOI: 10.1016/j.tube.2017.11.004
Sekaggya-Wiltshire, Christine ; Lamorde, Mohammed ; Kiragga, Agnes N. ; Dooley, Kelly E. ; Kamya, Moses R. ; Kambugu, Andrew ; Fehr, Jan ; Manabe, Yukari C. ; Castelnuovo, Barbara. / The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. In: Tuberculosis. 2018 ; Vol. 108. pp. 77-82
@article{f8a0b4a80a754cf08130059727d8f397,
title = "The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs",
abstract = "Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.",
keywords = "Anti-tuberculosis drugs, Concentrations, Treatment outcomes",
author = "Christine Sekaggya-Wiltshire and Mohammed Lamorde and Kiragga, {Agnes N.} and Dooley, {Kelly E.} and Kamya, {Moses R.} and Andrew Kambugu and Jan Fehr and Manabe, {Yukari C.} and Barbara Castelnuovo",
year = "2018",
month = "1",
doi = "10.1016/j.tube.2017.11.004",
volume = "108",
pages = "77--82",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs

AU - Sekaggya-Wiltshire,Christine

AU - Lamorde,Mohammed

AU - Kiragga,Agnes N.

AU - Dooley,Kelly E.

AU - Kamya,Moses R.

AU - Kambugu,Andrew

AU - Fehr,Jan

AU - Manabe,Yukari C.

AU - Castelnuovo,Barbara

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.

AB - Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.

KW - Anti-tuberculosis drugs

KW - Concentrations

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=85033383048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033383048&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2017.11.004

DO - 10.1016/j.tube.2017.11.004

M3 - Review article

VL - 108

SP - 77

EP - 82

JO - Tuberculosis

T2 - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

ER -